Astrum

Founded in 2016, Astrum is a global CRO formed by uniting several experienced European CROs under one brand to address fragmentation and quality issues in clinical trial execution. It offers a full spectrum of clinical development services, leveraging audited facilities including a major Phase I unit in Porto and a broad partner network to ensure speed, compliance, and data quality. The company strategically positions itself as a partner for both emerging biotechs needing investor-ready data packages and large pharma companies requiring multi-country trial execution. Its value proposition centers on adaptive solutions, regulatory excellence (EMA, FDA, ANVISA), and a proven track record across hundreds of completed trials.

Integrated operational service platform combining audited clinical facilities (including a major Phase I unit in Porto), a global partner network, and deep regulatory expertise (EMA, FDA, ANVISA) to deliver adaptive, high-quality clinical trial execution and data packages.

Astrum competes in the crowded global CRO market against large, publicly-traded players (e.g., IQVIA, ICON, Parexel) and numerous niche or regional CROs. Its differentiation is based on a strategic, partnership-focused approach, deep European regulatory expertise, and a value proposition tailored to the milestone-driven needs of emerging biotech companies.